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ABSTRACT
Every cell in an individual has largely the same genomic sequence and yet cells in
different tissues can present widely different phenotypes. This variation arises
because each cell expresses a specific subset of genomic instructions. Control over
which instructions, or genes, are expressed is largely controlled by transcriptional
regulatory pathways. Each cell must assimilate a huge amount of environmental
input, and thus it is of no surprise that transcription is regulated by many
intertwining mechanisms. This large regulatory landscape means there are ample
possibilities for problems to arise, which in a medical context means the
development of disease states. Metabolism within the cell, and more broadly, affects
and is affected by transcriptional regulation. Metabolism can therefore contribute to
improper transcriptional programming, or pathogenic metabolism can be the result
of transcriptional dysregulation. Here, we discuss the established and emerging
mechanisms for controling transcription and how they affect metabolism in the
context of pathogenesis. Cis- and trans-regulatory elements, microRNA and
epigenetic mechanisms such as DNA and histone methylation, all have input into
what genes are transcribed. Each has also been implicated in diseases such as
metabolic syndrome, various forms of diabetes, and cancer. In this review, we discuss
the current understanding of these areas and highlight some natural models that
may inspire future therapeutics.
Subjects Biochemistry, Genetics, Molecular Biology, Metabolic Sciences
Keywords Epigenetics, Cancer, Diabetes, Metabolism, Metabolic syndrome, Transcriptional
control, Transcription factors
INTRODUCTION
The identity and function of each cell depends on the expressed genes within its genome.
Gene expression plays a major role in mediating virtually every cellular process; for
example, cell proliferation, development, aging, responses to external stimuli, and diseases
of many kinds. As such, gene expression itself must be under rigorous and coordinated
controls to prevent wrongful transcription. Numerous studies have identified multiple
mechanisms that are involved in regulating gene expression including the role of the
transcriptional machinery, availability of transcription factors, co-factors, and DNA
binding elements, accessibility of the DNA to the transcriptional machinery, messenger
RNA processing and stability, transportation and translation (Mitchell & Tjian, 1989;
How to cite this article Hawkins et al. (2018), Transcriptional regulation of metabolism in disease: From transcription factors to
epigenetics. PeerJ 6:e5062; DOI 10.7717/peerj.5062
Submitted 9 March 2018
Accepted 4 June 2018
Published 15 June 2018
Corresponding author
Kenneth B. Storey,
Kenneth_Storey@carleton.ca
Academic editor
Joanna Moraczewska
Additional Information and
Declarations can be found on
page 24
DOI 10.7717/peerj.5062
Copyright
2018 Hawkins et al.
Distributed under
Creative Commons CC-BY 4.0
Rippe, von Hippel & Langowski, 1995; Guhaniyogi & Brewer, 2001; Butler & Kadonaga,
2002; Villard, 2004; Berger, 2007; Ko¨hler & Hurt, 2007; Bentley, 2014). Abnormalities in any
of the above processes may still occur even under stringent regulation which may give rise
to various pathologies. Therefore, it is imperative to fully understand the role of
transcriptional programming to understand the cause of various medical conditions and
find potential remedies. Interest in understanding individual transcriptional mechanisms
has been increasing in the past few decades and numerous laboratories are working to
understand the effect of various environmental influences, gene mutations, and gene
dysregulation in relation to transcription. In this review, we will discuss the effect of
transcriptional dysregulation in disease and how understanding transcriptional controls
will help solve current medical dilemmas.
SURVEY METHODOLOGY
In this review, we discuss the intersection of transcriptional control, metabolism, and
disease. Our discussion is structured to survey past and current contributions relating to
classic transcriptional regulatory mechanisms such as cis- and trans-regulatory elements
and the recent emergence of epigenetics with respect to disease metabolism. We add
insight into future basic and therapeutic research directions with inspiration from natural
systems for metabolic control. We used standard literature search tools (PubMed, Google
Scholar, etc.) to identify relevant information and combinatorial keyword patterns to
determine research trends.
CONTROL OF TRANSCRIPTION BY CIS-REGULATORY
ELEMENTS
There are several regulatory elements within a genome that facilitate transcription. The
human genome contains approximately 19,000 protein coding genes (which comprise
only ∼1–2% of the entire genome) and a small percentage of non-protein coding genes
that serve as regulatory elements (Ezkurdia et al., 2014; Palazzo & Lee, 2015). Gene
expression depends on the structure of the genome and whether different genes are
accessible to the transcriptional machinery. Studies on epigenetic regulation of the
genome have been increasing exponentially in the past decade and emerging work is
outlining the role of epigenetics in development, survival, and disease (Jaenisch & Bird,
2003; Esteller, 2007; Portela & Esteller, 2010;Wijenayake & Storey, 2016; Hawkins & Storey,
2018). We will explain the role of epigenetic controls on transcription in detail later in
this review.
Transcription in eukaryotes is carried out by RNA polymerase II and aided by several
general transcription factors that collectively make the transcription initiation complex.
Genes usually contain several DNA regulatory elements, called the cis-regulatory
elements within them. These regulatory sites encompass a promoter region which
contains both the proximal promoter elements and the core promoter, and a distal
regulatory element region which encompasses the locus control regions (LCRs),
insulators, silencers, and enhancers (Maston, Evans & Green, 2006) (Fig. 1). Within
the core promoter region is often found the TATA box, a short DNA motif that is
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within ∼30 nucleotide of the transcription start site in eukaryotes where the general
transcription factors will bind. Upstream of the core promoter is the orientation-
dependent proximal promoter, where several transcriptional co-activators and regulatory
proteins bind to facilitate or prevent transcription. Other cis-regulatory elements exist
with varying distances to modulate transcription. During development or in response
to an external or internal stimulus, some genes are expressed together as a cluster. The
LCRs are different cis-regulatory elements located within the distal regulatory elements
region. These elements function by facilitating the expression of a cluster of genes in a
copy-number and tissue-specific manner with respect to the physiological needs of the
tissue (Li et al., 2002). Furthermore, LCRs encompass the insulator, silencer, and enhancer
elements. Insulators function by “insulating” the expression of specific genes and
create a barrier that allows the transcription of the desired gene but blocks the expression
of the neighboring gene (Maston, Evans & Green, 2006). Silencers will bind repressors
and repress transcription often in an orientation and distance independent manner,
although some silencers may be more stringent (Maston, Evans & Green, 2006). Enhancers
as their name suggests, will enhance transcription. These cis-regulatory elements are
located at various distances from the target gene and contain short spans of DNA
sequences that function as binding sites for specific transcription factors (both trans-
activating and repressing factors) necessary to facilitate sufficient transcription (Sakabe,
Savic & Nobrega, 2012). The importance of these cis-regulatory elements has been outlined
in many cellular processes including embryogenesis, development, and pathological
conditions (Villard, 2004; Borok et al., 2010; Sakabe, Savic & Nobrega, 2012; Petit, Sears &
Ahituv, 2017). Overall, the presence of these different regulatory elements within the
genome creates an intricate network of communications to either facilitate or repress
transcription in an organized manner.
As such, while most mutations within the genome are not associated with negative
outcomes, a few mutations that occur within the regulatory elements (i.e., the cis/
trans-regulatory elements) of specific genes could disturb gene expression, thus resulting
in a pathological state. Indeed, genome-wide association studies found that single
nucleotide polymorphisms (SNPs) within the enhancer element of different genes is
associated with numerous diseases. SNPs within the enhancer element were shown to
influence the expression profile of specific genes by altering the transcription factor
binding sites for several transcription factors and other regulatory factors associated
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Figure 1 General representation of transcriptional regulatory elements. In eukaryotic transcription, the DNA is present in a three-dimensional
orientation where physical interaction between proteins occupying elements of the distal regulatory region and the promoters is possible. Study site:
LCRs, locus control regions. Full-size DOI: 10.7717/peerj.5062/fig-1
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with transcription (for review, Corradin & Scacheri, 2014). Numerous studies on diabetes,
metabolic syndrome, and cancers have shown the involvement of mutations in the
cis/trans-regulatory elements as well as microRNAs on the progression of these diseases.
Cis-regulation of diabetes and metabolic syndrome
Metabolic syndrome is a clustering of pathogenic phenotypes that co-occur in individuals
with risk of cardiovascular disease and type 2 diabetes (T2D). In general, definitions
include impaired glucose and lipid regulation, increased blood pressure, low HDL
cholesterol levels, and increased adiposity (Alberti et al., 2009; Kaur, 2014), and are
associated with significantly increased all-cause mortality (Malik et al., 2004; Hui, Liu &
Ho, 2010). The prevalence of these conditions is highly dependent on demography, but
recent estimates put the number of American adults with metabolic syndrome on an
upward trend at almost 35% (Aguilar et al., 2015). Although genetics contribute to some
predisposition to the development of metabolic syndrome and each of its components
(Pollex & Hegele, 2006; Sladek et al., 2007; Day & Loos, 2011), environmental factors such
as a sedentary lifestyle, poor intrauterine conditions, and overnutrition are all highly
associative and may turn out to be the best targets for intervention (Aude, Mego & Mehta,
2004; Grundy et al., 2005; Tjønna et al., 2008). As such, while the environment and
genetic predisposition can also play a role in disease manifestation, mutations within the
non-coding elements of genes can be associated with causing pathologies. One example of
such pathology is diabetes. The bone morphogenic protein receptor 2 (BMPR2) is a
member of the transforming growth factor beta (TGFb) receptor family that has been
found to play a significant role in pulmonary arterial hypertension (PAH), obesity, and
insulin resistance (Schleinitz et al., 2011;West et al., 2013, 2014; Viales et al., 2015). Indeed,
studies have found that over 80% of heritable PAH and 20% of idiopathic PAH patients
have mutations within their BMPR2 gene (Machado et al., 2009; Pfarr et al., 2011).
A recent study on families with history of PAH showed mutations within the BMPR2 gene
as well as a novel mutation within the promoter of BMPR2 (c.669G>A) (Viales et al.,
2015). The same study concluded that patients that carried both mutations had heritable
PAH and manifested severe clinical signs of this disease. Moreover, distal regulator
elements were shown to play a significant role in regulating gene expression with respect
to obesity. For example, SNPs within long-range enhancers in the fat mass and obesity-
associated protein (FTO) directly affected the expression of IRX3 (Smemo et al., 2014).
IRX3 is a transcription factor that has been previously shown to modulate body mass and
composition, as shown by the lean phenotype of IRX3 deficient mice (Smemo et al., 2014).
The same study showed that mice deficient in IRX3 have an increase in their basal
metabolic rates and are prone to fat mass loss.
Pancreatic dysregulation is associated with various forms of diabetes and is partly
mediated by abnormal transcription (Federici et al., 2001; Weedon et al., 2014; Stitzel et al.,
2015). The pancreas is composed of two major compartments: the exocrine and endocrine
compartments. The exocrine compartment is divided into two major cell types; the acinar
cells which secrete digestive zymogens and the epithelial cells which secrete bicarbonate in
order to neutralize the stomach acids entering the small intestine (Bastidas-Ponce et al., 2017).
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The endocrine compartment of the pancreas is responsible for secreting appropriate
hormones to regulate glucose metabolism and homeostasis. The islets of Langerhans are
composed of several cell types which mainly include the alpha, beta, delta, pancreatic
polypeptide, and epsilon cells and carry out the endocrine function of the pancreas
(Stitzel et al., 2015; Bastidas-Ponce et al., 2017). These endocrine cells mediate glucose
homeostasis by secreting the hormones glucagon, insulin, somatostatin, pancreatic
peptide or ghrelin (Bastidas-Ponce et al., 2017). While the coordinated secretion of these
hormones regulates metabolic homeostasis in organisms, improper or imbalance in
secretion of any of these hormones can promote responses characteristic of diabetes
mellitus. Adequate and appropriate secretion of these hormones relies on the proper
development of the associated cells, therefore any mutations that halt or interrupt the
development of these cells can lead to diabetic pathologies. For example, the pancreas-
specific transcription factor 1a (PTF1a) is responsible for proper formation of the
pancreas during embryonic development and is crucial for the development of both the
endocrine and the exocrine compartments (Masui et al., 2008; Weedon et al., 2014; Gonc
et al., 2015). Using linkage analysis and whole-genome sequencing of patients with
pancreatic agenesis, it was shown that several recessive mutations within the
developmental enhancer region of the PTF1A gene abolishes transcription factor binding,
thus leading to improper development of the pancreas, causing diabetes (Weedon et al.,
2014). Moreover, the BLK gene encodes for a nonreceptor tyrosine-kinase belonging to the
Src family of proto-oncogenes (Gauld & Cambier, 2004). This gene was also found to be
expressed in various cell types including beta cells where it promotes insulin synthesis in
response to glucose uptake (Borowiec et al., 2009). Patients with maturity-onset diabetes
of the young (MODY) were shown to have noncoding mutations within the BLK locus
which resulted in disruption in insulin synthesis when glucose levels were high (Borowiec
et al., 2009). The same study showed that overexpression of BLK in MIN6-beta cells
caused an increase in the protein levels of two transcription factors, PDX-1 and NKX6.1.
PDX-1 was previously shown to regulate the expression of several beta cell genes including
NKX6.1 (Wang et al., 2001). NKX6.1 regulates glucose-simulated insulin secretion in beta
cells and together with PDX-1 enhance mass as well as the function of the pancreatic beta
cells (Wang et al., 2001; Schisler et al., 2005).
Cis-regulatory elements in cancer
As medical science advances and screening for genetic abnormalities becomes easier, more
and more information is being accumulated on the origins of various diseases and
syndromes and how normal metabolic processes are affected under such circumstances.
The completion of the encyclopedia of DNA elements (ENCODE) helped with providing
a more thorough understanding of various regulatory elements within the human
genome (ENCODE Project Corsortium, 2012; Roadmap Epigenomics Consortium et al.,
2015). Data repositories like this provided the much-needed step forward in comparing
normal vs. “abnormal” metabolic regulation that occur within a cell’s genome. Recently,
several studies have been published that focus on the effect of mutations within the
cis-regulatory elements and how these mutations affect transcription (Babitt et al., 2006;
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Horn et al., 2013; Perera et al., 2016). For example, whole-genome sequencing of several
malignant melanomas showed that in 17 of 19 cases analyzed mutations (C228T and
C250T) were found within the telomerase reverse transcriptase (TERT) promoter
(Babitt et al., 2006; Berger, 2007). Another independent study on the TERT promoter of
melanomas showed that 125 of the 168 human cancer cell lines screened contain the same
somatic mutations (Horn et al., 2013). These mutations generated a de novo consensus
sequence within 100 base pairs of the transcriptional start site that binds to the E-twenty-
six transcription factors within the promoter of the TERT gene (Babitt et al., 2006;
Horn et al., 2013). Under normal circumstances telomerase activity is repressed in most
human cells; therefore, chromosomes are shortened with every round of cell division and
this leads to either halting replication or promoting apoptosis when telomeres become
shorter in length (Shay & Wright, 2011; Chen et al., 2018). When cells are cancerous, their
telomerase activity is significantly increased which allows the chromosomes to maintain
lengthy telomeres, thereby immortalizing the cells (Hahn & Meyerson, 2001; Shay &
Wright, 2011). Moreover, compared to the wild-type TERT promoter, the mutations
observed increased the transcription of this gene by 2 to 4 fold (Babitt et al., 2006).
Altogether, these studies show that mutations within the promoter region of the TERT
gene allow an overall increase in production and therefore activity of telomerase, which
accounts for yet another explanation of how cancer cells maintain lengthy telomeres
(Liu, Yuan & Xu, 2016). The human TERT is also involved in regulating the pentose
phosphate pathway; where NADPH and other co-factors required for fatty acid synthesis,
RNA synthesis and lipogenesis are generated (Ahmad et al., 2016). The same study showed
that inhibition of TERT attenuated the phosphorylation of glycogen synthase in addition
to attenuating the expression of glucose-6-phosphate dehydrogenase and transketolase
in glioma cells. These findings were congruent with the overexpression of transketolase
and decreases in glycogen levels in glioblastoma multiforme patients harboring the
C228T and C250Tmutation in their TERT promoter (Ahmad et al., 2016). As such, the
presence of such mutation does not only promote cancer cell mortality by increasing
telomerase activity but also by reprograming the cell’s metabolic response to promote
its progression.
CONTROL OF TRANSCRIPTION BY TRANS-REGULATORY
ELEMENTS
Trans-regulatory elements are other factors that contribute to regulating transcription
under a variety of conditions. While mutations within the cis-regulatory elements alone
can be associated with diseases, mutations within the proteins that bind those elements
can also be associated with different pathologies. TFIID is part of a multi-subunit complex
that contains a TATA-binding protein along with other factors that assemble at the
promoter of genes to recruit RNA polymerase II to the transcription start site. Subsequent
transcription only requires RNA polymerase II, TFIIF and TFIIB as TFIID, TFIIH and
Mediator are retained within the promoter. While this assembly is sufficient for basal
levels of transcription, activators can bind to enhancers upstream of the promoter
and increase the expression of their target genes (Ma, 2011). These activators are also
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called transcription factors and they bind either as monomers, heterodimers or
homodimers to a 6–12 nucleotide consensus sequence within the enhancer region
upstream of the core promoter to enhance the transcriptional activity of target genes.
Other studies have also shown that activators have the ability to recruit chromatin
modifiers in order to facilitate transcription (Bowman & McKnight, 2017). While
mutations within the binding sites of transcription factors can prevent protein-DNA
complex formation; mutations within the transcription factors themselves are also
associated with disease development. Co-activators are intermediary proteins or
complexes that can interact with activators and enhance transcription (Kim et al., 2001b;
Li & Susztak, 2018). Some coactivators have been shown to increase transcription by
promoting the recruitment of RNA polymerase II or activators whereas others recruit
chromatin modifiers that relax the structure of the DNA for the transcriptional machinery
(Krasnov et al., 2016). Alternatively, repressors and corepressors also play roles in
regulating transcription. Repressors inhibit gene expression selectively by binding to
the repressor element of the DNA thus preventing the binding of the transcriptional
machinery or by recruiting enzyme modifiers that would render the DNA inaccessible to
the transcriptional machinery. Transcription partly depends on the interplay between
activators and repressors, therefore any inappropriate association of these regulators with
their DNA binding elements can result in unfavorable consequences.
Trans-regulatory elements in diabetes and metabolic syndrome
Maturity-onset diabetes of the young (MODY) is a rare monogenic disorder that follows
an autosomal-pattern of inheritance and occurs in individuals younger than 25 years of
age (Amed & Oram, 2016). The onset of MODY is not dependent on insulin but is caused
by mutations in several genes that result in defective beta cells. As such, one of the major
clinical features of MODY is hyperglycemia; however, since MODY shares common
features as T1D and T2D, it is often misdiagnosed (Amed & Oram, 2016). The most
common mutations associated with MODY occur in at least one of the following
components: HNF4a (hepatocyte nuclear factor 4 alpha, MODY1), glucokinase
(MODY2), HNF1a (MODY3), insulin promoter factor 1 (IPF-1, MODY4), HNF1b
(MODY5) or neurogenic differentiation 1/b-cell E-box transactivator 2 (NeuroD1,
BETA2, MODY6) (Fajans, Bell & Polonsky, 2001). HNF proteins are transcription factors
that are enriched in the liver but can be also found in several other tissues such as kidney
and pancreatic islets (Fajans, Bell & Polonsky, 2001). These transcription factors are
thought to play a significant role during development and adulthood. In beta cells, the
insulin gene and other genes involved in the transport of glucose and metabolism are
under HNF control. In the liver, these transcription factors regulate lipoprotein
biosynthesis and fatty acid metabolism (Stoffel & Duncan, 1997; Dukes et al., 1998; Miura
et al., 2006; Martinez-Jimenez et al., 2010; Yin et al., 2011). A previous study showed that
50% of Norwegian families with mutations in their HNF1a have clinical MODY3
(Bjørkhaug et al., 2003). The same study showed that two of these mutations prevented the
transcription factor from binding to DNA and five mutations prevented the transcription
factor nuclear translocation thereby reducing transcription of the target genes in both
Hawkins et al. (2018), PeerJ, DOI 10.7717/peerj.5062 7/44
cases. Moreover, mutations in the glucokinase enzyme are also associated with MODY.
Glucokinase is a glucose sensing enzyme that functions to transform glucose from the
blood to glucose-6-phosphate in beta cells (Amed & Oram, 2016). As such, inactivating
mutations within the glucokinase gene typically manifest hyperglycemia (Froguel et al.,
1993). Moreover, the IPF-1 transcription factor has been shown to regulate the
transcription of several targets including the insulin, glucokinase, and the glucose
transporter 2 genes (St-Onge, Wehr & Grusst, 1999). For this reason, mutations within the
IPF-1 gene that abolish its transcriptional activity could result in the onset of various
diabetic pathologies including MODY. A case study showed that autosomal dominant
mutations within the NeuroD1 (BETA2) gene were causing a dysregulation in the
expression of the insulin gene, leading to the development of diabetes before the age of
25 (Malecki et al., 1999). In another case, dysregulation in PGC-1a, a coactivator of
PPAR and PPARa which are involved in adipogenesis and mitochondrial fatty acid
oxidation respectively, was shown to increase the risk of type II diabetes (Ek et al., 2001).
Furthermore, PGC-1a was shown to play a role in improving glucose homeostasis and
fuel storage in skeletal muscle (Wende et al., 2007; Summermatter et al., 2013). PGC-1a
can bind to the MEF2C transcription factor and function as a co-activator where it will
facilitate the expression of GLUT4 (glucose transporter 4) (Michael et al., 2001). The
polymorphism Gly482Ser decreases the binding affinity of PGC-1a to MEF2C, thereby
decreasing GLUT4 expression and increasing the risk of developing type II diabetes (Hara
et al., 2002; Muller et al., 2003; Zhang et al., 2010).
Differential activities in certain transcriptional repressors can also be associated with
metabolic abnormalities. For example, FOXA2 (Forkhead box A2, also known as HNF3b)
is a known transcription factor that plays a role in regulating insulin secretion, sensitivity
and glucose/lipid metabolism (Lantz et al., 2004; Puigserver & Rodgers, 2006). Recently,
several studies have identified FOXA2 as a transcriptional repressor where its association
with specific genes prevents their transcription (Rausa, Tan & Costa, 2003; Guo et al.,
2012). For example, FTO is an important gene that has been associated with regulating
body mass. A study by Guo and colleagues showed that FOXA2 overexpression was
associated with significant downregulation of FTO promoter activity whereas FOXA2
depletion allowed FTO expression, thereby providing evidence that FOXA2 is a negative
repressor of the FTO gene (Guo et al., 2012). FTO was previously shown to be involved in
several metabolic syndrome-related conditions such as diabetes, insulin signaling,
lipogenesis, and mitochondrial dysfunction, whereby FTO overexpression was observed
(Bravard et al., 2011; Akbari et al., 2018). In this case, the lack of appropriate repressor
response was associated with untimely expression of target genes, which resulted in
clinical manifestation of diseases.
Trans-regulatory elements in cancer
Numerous studies have outlined the role of trans-regulatory elements in cancer
development (Girnun, 2012; Bradner, Hnisz & Young, 2017; Sciortino et al., 2017; Safe et al.,
2018). The availability of tools to easily sequence cancer genomes has provided ample
information on the mutations and dysregulations that promote cancer development.
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Transcription factors play a significant role in differentiation and determining cell fate.
For example, P53 is a transcription factor that is responsible for expressing target genes
that inhibit the cell cycle and induce apoptosis; however, studies have shown that this
transcription factor is one of the most commonly mutated in cancers (Sionov & Haupt,
1999; Ozaki & Nakagawara, 2011; Vogiatzi et al., 2016). Under normal circumstances,
P53 is present at low levels, but upon induction of DNA damage, its expression and
activity increase (Sionov & Haupt, 1999; Ozaki & Nakagawara, 2011; Vogiatzi et al., 2016).
The cell cycle arrest properties of P53 helps to repair DNA damage under circumstances
that promote genomic instability and the pro-apoptotic properties of this transcription
factor work to eliminate those cells that carry a substantial amount of DNA damage in
order to prevent the transfer of deleterious mutations to daughter cells (Ozaki &
Nakagawara, 2011). Several mutations within P53 abolish its tumor suppressing activities
and promote its tumor progressive function (Gasco, Shami & Crook, 2002; Lim et al., 2009;
Ozaki & Nakagawara, 2011; Vogiatzi et al., 2016). Indeed, over 50% of cancers carry
mutations within the P53 gene, however these mutations in most cancers create a
stably functional P53 that functions better than the wildtype P53, is resistant to drug
treatment, and can cause metastasis (Brosh & Rotter, 2009; Oren & Rotter, 2010). The role
of P53 has been studied extensively and one study showed that cancerous P53 was
associated with gain of function mutations whereby it caused the expression of
ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) (Vogiatzi et al., 2016).
The same study found that ENTPD5 function promotes the folding of N-glycoproteins
which is necessary for the proliferation, tissue remodeling, and metastasis of tumors.
Furthermore, P53 also plays a role in metabolism by inducing the expression of metabolic
genes and suppressing the production of reactive oxygen species (Li et al., 2012).
Interestingly, several studies have demonstrated that while some mutations may interrupt
the activity of P53 in regulating the cell cycle and apoptosis, the same mutations may not
necessarily have a negative influence on its activity in regulating the uptake and
catabolism of glucose and suppressing the production of reactive oxygen species (Li et al.,
2012; Napoli & Flores, 2017; Itahana & Itahana, 2018). As such, mutations within the P53
gene may differentially regulate its transcriptional activity and favor the expression of a
subset of genes leading to metabolic deregulation necessary for oncogenesis (Gatto,
Schulze & Nielsen, 2016).
Moreover, HBP1 is a transcriptional repressor that regulates cellular proliferation
and inhibition of the Wnt signaling pathway (Shih, Tevosian & Yee, 1998; Sampson et al.,
2001; Shih et al., 2001; Escamilla-Powers et al., 2010). Repressors also play a significant
role in controlling transcription. HBP1 binding to the promoters of WNT, b-catenin,
GSK3b or LEF/TCF prevents their expression, thereby rendering Wnt signaling ineffective
(Sampson et al., 2001). In addition, the same study showed that HBP1-mediated Wnt
signaling suppression prevented cyclin D1 and c-myc gene expression. A decrease in HBP1
levels has been associated with enhanced invasion and tumorigenesis in breast cancers,
partly by causing a dysregulation in Wnt signaling (Paulson et al., 2007). Moreover, HBP1
was also reported to play a role in regulating mitochondrial biogenesis and regulation.
Indeed, cells deficient in Hbp1 showed a significant decrease in mitochondrial respiration
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and an approximate 29% increase in the oxygen consumption rate (Dong et al., 2016). As
such, mutations within HBP1, that could interrupt its activity could result in serious
cellular damage.
MICRORNA REGULATION OF TRANSCRIPTION
The human genome contains both coding and non-coding RNAs. Apart from transfer and
ribosomal RNAs, multiple types of regulatory non-coding RNAs exist (Kowalczyk, Higgs
& Gingeras, 2012) including long non-coding RNAs and microRNAs. These two types of
non-coding RNAs have been shown to play a significant role in maintaining cellular
homeostasis and dysregulation of their activity has been linked to different disease
conditions (Li et al., 2010; Ardekani & Naeini, 2010; Esteller, 2011; Wang, 2013; Huarte,
2015; Sun & Wong, 2016; Feng, Xing & Xie, 2016). For the purposes of this review, we will
focus on the role of microRNAs in regulating metabolism and disease.
MicroRNAs are small non-coding RNAs that negatively regulate gene transcripts (He &
Hannon, 2004) and have regulatory actions in huge numbers of cell functions including
development, cellular metabolism, stress response, and disease (He & Hannon, 2004;
Wienholds & Plasterk, 2005; Ardekani & Naeini, 2010). MicroRNAs are originally
transcribed as pri-microRNAs that are then cleaved by the Drosha enzyme to form a 70
nucleotide long precursor microRNA containing hairpin structures (He &Hannon, 2004).
These precursors are then transported to the cytoplasm via exportin 5 where they are
cleaved further to form short (21–25 nt) single stranded RNAs that are capable of binding
to the RNA-induced silencing complex and target mRNA transcripts based on
complementarity (He&Hannon, 2004). The fate of the mRNA transcript is determined by
the degree of complementarity between the microRNA and its target transcript. If
complementarity between the two is high, the microRNA will bind to the 3′UTR of the
transcript and direct it to be degraded, whereas if there is partial complementary, the
transcript will be sequestered in p-bodies and stress granules for future retrieval (Liu et al.,
2005). Studies have shown the involvement of microRNAs in several cellular processes
including autophagy, apoptosis, diabetes, cancer, muscle atrophy, and development
(Li et al., 2010; Ardekani & Naeini, 2010; Wang, 2013; Su et al., 2015; Feng, Xing & Xie,
2016). Each microRNA can have several different mRNA targets whereas each mRNA can
be targeted by multiple microRNAs. MicroRNAs can target the transcripts of several
transcription factors and other cis-regulatory elements, thereby preventing them from
regulating transcription appropriately. Moreover, microRNAs can also inhibit the mRNA
transcripts that are produced by certain transcription factors with respect to the cell’s
environment. While regulation by microRNA can be crucial for survival and
development, dysregulation of this regulatory factor can be associated with disease.
MicroRNA in diabetes and metabolic syndrome
With the advancement of technology and the availability of several cancer genomes, it is
becoming easier to decipher the role of non-coding RNAs in cells. Pancreatic beta cells
play a significant role in maintaining glucose homeostasis by releasing insulin and several
microRNAs have been shown to promote apoptosis in beta cells, thereby leading to
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diabetes (Feng, Xing & Xie, 2016). The programmed cell death protein 4 (PDCD4) is
involved in both translation (by suppressing translation initiation) and transcription (by
binding to promoters) (Ozpolat et al., 2007; Lankat-Buttgereit & Go¨ke, 2009; Jo et al.,
2016). A study by Ruan et al. (2011) showed that nuclear factor kB (NFkB) promotes
the expression of miR-21, where this microRNA will then prevent the expression of
PDCD4. PDCD4 deficiency in islet beta cells was associated with a decrease in
proapoptotic BAD, BAX, and BID transcript levels while increasing the mRNA expression
of the antiapoptotic BCLXL (Ruan et al., 2011). This example shows how transcriptional
regulation of miR-21 by NFkB indirectly prevented apoptosis and abolished pancreatic
beta cell apoptosis to prevent development of type 1 diabetes. Moreover, miR-30d was
shown to be regulated by glucose and is involved in promoting insulin gene transcription
(Tang et al., 2009). A follow up-study showed that miR-30d caused an increase in MAFA,
a key transcription factor that increases the expression of the insulin gene in beta cells
(Zhang et al., 2005; Zhao et al., 2012). It was also reported that the tumor necrosis factor a
(TNF-a) suppresses insulin transcription (Tsiotra, Tsigos & Raptis, 2001; Lawrence et al.,
2011). Interestingly, Zhao et al. (2012) found an increase in MAFA when miR-30d levels
were high since this microRNA targets a member of the TNF-a activated kinase, the
mitogen-activated protein 4 kinase 4 (MAP4K4), thereby alleviating an inhibitory effect
on MAFA. This is yet another regulatory mechanism whereby the expression of one
microRNA positively regulates transcription by targeting the specific inhibitory factors
involved.
Obesity is associated with inflammatory and non-inflammatory factors that are
regulated by various mechanisms. Gene expression of different targets associated with
obesity is regulated at various molecular levels and is induced with respect to
environmental stimuli. The C–C motif chemokine ligand 2/monocyte chemoattractant
protein 1 (CCL2/MCP-1) has been documented to regulate metabolism, inflammatory
responses, obesity, and insulin resistance amongst others (Rull et al., 2010). A study by
Arner et al. (2012) showed several microRNAs that had differential regulation in obesity,
nine of which were shown to affect CCL2 secretion from adipocytes. The same study
found that overexpression of several microRNAs caused a reduction in CCL2 secretion.
MiR-1126 regulated CCL2 expression by associating with its 3′ untranslated region while
miR-193b also regulated CCL2 expression by targeting other transcription factors
associated with inducing its expression (Arner et al., 2012). This is yet another example of
how microRNAs can both directly and indirectly affect the expression of target genes by
modulating the activity of other regulatory elements that facilitate transcription.
MicroRNA and cancer
A recent study showed that resistance to chemotherapeutic drugs via P53 may be
mediated by microRNAs (Donzelli et al., 2012). The study found that mutant P53 is
responsible for inducing the expression of miR-128-2 that can, in turn, lead to inhibition
of apoptosis and thereby promote resistance to several cancer therapeutics such as
cisplatin, doxorubicin, and 5-fluorouracyl treatments. For example, miR-128-2 targets
the transcript of E2F5, a transcriptional repressor to p21waf1 (Donzelli et al., 2012).
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The same study showed that miR-128-2 binds to the E2F5 transcript, thereby preventing it
from being translated into proteins. A decrease in E2F5 protein levels was associated
with the induction of the p21waf1 promoter activity, leading to overexpression of this
anti-apoptotic target in response to the therapeutics. Furthermore, other studies have
shown that inappropriate downregulation of specific microRNAs can cause an increase
in the expression of their targets; thereby causing a systemic imbalance. For example,
miR-101 has been shown to regulate the expression of SUB1/PC4 (Chakravarthi et al.,
2016). SUB1/PC4 has several functions including DNA replication, repair and
transcription but for the purposes of this review, we will restrict our discussion to its
transcriptional co-activating functions (Conesa & Acker, 2010). As a co-activator,
SUB1/PC4 regulates transcription by facilitating the interaction between the general
transcription machinery and activators, however the role of SUB1/PC4 in promoting
transcriptional repression is also documented (Werten et al., 1998; Conesa & Acker, 2010).
A study showed that overexpression of SUB1 in prostate cancer was associated with
cellular proliferation by facilitating the expression of several oncogenes (Chakravarthi
et al., 2016). The same study reported that a decrease in expression of miR-101 was
responsible for the increase in SUB1/PC4 levels; thereby elucidating a control mechanism
whereby the wrongful overexpression of a coactivator can manifest in cancer progression.
Moreover, a study by Majid et al. (2010) outlined a novel role for microRNAs in tumor
suppression. This study showed that overexpression of miR-205 was associated with
induction of apoptosis, proliferation arrest, and impairment of metastatic abilities. More
interestingly, miR-205 was shown to associate with the promoters of IL24 and IL32,
thereby inducing their expression. Both IL24 and IL32 have tumor suppressing properties
where reduction in IL24 levels has been observed in breast cancers and was associated with
poor prognosis and severe clinical outcomes (Patani et al., 2010). IL32 showed conflicting
data as some studies have showed its involvement in inducing T cell apoptosis while
others show its activation to be linked to metastasis in colorectal cancers (Goda et al.,
2006; Yang et al., 2015). Regardless of its pro- or anti-cancer functions, IL32 expression
was shown to be enhanced by miR-205 expression as this microRNAwas shown to bind to
the IL32 promoter (Majid et al., 2010).
Hence, transcription can be partly regulated by cis and trans-regulatory elements as well
as microRNAs. The proper communication between these factors is necessary for
appropriate gene expression and any dysregulation in one or more of these factors could
manifested in a pathological condition. Regulation of transcription happens at many
levels and while we discussed the role of cis/trans-regulatory elements as well as
microRNAs, it is also imperative to cover the role of epigenetic regulation in mediating
transcription.
EPIGENETIC REGULATION OF METABOLISM IN DISEASE
Research into the field of epigenetics has begun to reveal the mechanisms that allow a
wide range of phenotypes to arise from identical genomic information. It has long been
known that these phenotypic differences, between cell-types for example, are due to
differential expression of subsets of genes from the common genomic pool and their
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interaction with the environment (Fig. 2), but how exactly each subset is chosen has
remained elusive. Signals from the environment are programmed into the epigenetic
“memory” to affect gene expression, and are necessary for processes such as cellular
differentiation, development, and proper alignment of metabolic machinery to
nutritional availability, among others. Epigenetic mechanisms, such as DNA methylation
and histone modifications, add layers of regulatory information onto the DNA sequence.
Genomic information is passed from generation to generation through DNA replication,
and in a similar sense, these additional layers can transmit gene regulatory information
mitotically, and in some cases, transgenerationally (Skinner, 2011). Due to the power,
complexity, and sometimes fragility of the epigenome, we are becoming increasingly
aware of its involvement in a substantial number of pathologies. For example, the
epidemic increase in people with metabolic syndrome seen in the past several decades
may, at least in part, be attributable to epigenomic misalignment between nutritionally
deficient intrauterine conditions, and high-caloric diets later in life. Originally met with
much skepticism, the “thrifty phenotype” hypothesis (Hales & Barker, 1992) postulated
that maternal malnutrition programmed the developing fetus to be hypersensitive to
macro- and micronutrients present in what was expected to be a nutrient sparse
environment. When this anticipatory adaptation met a modern high-carbohydrate,
high-fat diet, the result was increased susceptibility to T2D, obesity, and other hallmarks
of metabolic syndrome. Originally supported by epidemiological evidence (Hales &
Barker, 2001), the development of new molecular biology techniques and epigenetic
discoveries have shown direct evidence for the “thrifty phenotype”, where epigenetic
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Figure 2 Intrinsic and environmental signals integrate through the epigenome to produce distinct
phenotypes from identical genomic information. Standard cellular, biochemical, physiological, and
developmental signals integrate with environmental factors such as diet, toxin exposure, stress, social
interactions and developmental conditions through the epigenome to produce numerous phenotypes.
Full-size DOI: 10.7717/peerj.5062/fig-2
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mechanisms link early life experience to glucose-insulin dysregulation (Park et al., 2008;
Raychaudhuri et al., 2008; Heijmans et al., 2008; Ding et al., 2012). This “thrifty
phenotype” is part of a broader study of the developmental origins of health and disease
(DOHaD) that has spawned from epidemiological studies connecting normal and
abnormal environmental conditions at a broad range on developmental stages to the
development of disease (Wadhwa et al., 2009). Below we will explore examples from the
DOHaD approach, such as the “thrifty phenotype,” where perturbations, genomically and
through the environment, are translated into epigenetic dysregulation of metabolism,
leading to disease.
DNA methylation and histone modification
Nucleosomes consist of 146 base pairs of DNA wrapped around an octamer complex of
histone proteins. These functional units of chromatin are not only needed for higher order
compaction of DNA during cell division, but are also essential for controlling gene
expression. Both major components of the nucleosome, DNA and histone proteins,
can be chemically modified by enzymes as part of a reader-writer-eraser paradigm.
Although the proteins that add, remove, and interpret the modifications are generally
distinct from each other, they form complex interaction, and regulatory networks. What
emerges is a propagative epigenetic program that recruits chromatin remodeling, gene
regulatory, and transcriptional machinery to dynamically regulate transcription in
response to intra- and extracellular stimuli.
DNA is methylated at the C5 position of cytosines, forming 5-methylcytosine (5mC),
and occurs mostly at CpG dinucleotides (Arand et al., 2012). DNA methylation occurs in
two contexts: the creation of new information via de novo methylation by the DNA
methyltransferase enzymes DNMT3A and DNMT3B (Okano et al., 1999), and the
duplication of that information during subsequent DNA replication by DNMT1. Once a
methylation pattern is established by de novo methyltransferases, the Watson–Crick
base pairing symmetry of the CpG dinucleotide allows DNMT1 to acts as a maintenance
methyltransferase, where it copies the previous methylation pattern onto the newly
synthesized strand during DNA replication (Robert et al., 2002). The inhibitory functions
of DNA methylation on gene transcription are mainly mediated by methyl-CpG-binding
domain containing proteins which recruit transcriptional corepressors, but there is
evidence that methylated DNA can also sterically hinder some transcription factor
binding (Watt & Molloy, 1988). DNA methylation is classically associated with gene
silencing, however, the function of 5mC may be more nuanced than once thought
depending on its position relative to gene regulatory elements and high density CpG
regions (CpG islands) (Jones, 2012; Schu¨beler, 2015).
Histone proteins can also be post-translationally modified in a variety of ways.
Histones have highly conserved N-terminal tails that protrude from the core of the
nucleosome and when modified can either regulate the structure of chromatin directly, or
serve to recruit effector proteins such as chromatin remodelers and transcription factors
(for review seeMartin & Zhang, 2005; Bannister & Kouzarides, 2011; Holt, Wang & Young,
2017). Although there are numerous histone modifications known (Kouzarides, 2007),
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and more being discovered each year (Tan et al., 2011; Chen, Miao & Xu, 2017), the
best-characterized modifications are histone lysine acetylation and methylation. Lysine
residues on histones are acetylated by histone acetyltransferases (HATs) and deacetylated
by histone deacetylases (HDACs). The effect of histone acetylation is twofold: (1) it creates
binding sites for factors involved in transcriptional regulation, typically in the context of
activation, and (2) addition of an acetyl-group neutralizes the positive charge of the
histone protein, weakening the histone-DNA interaction, relaxing chromatin
conformation, and ultimately increasing DNA accessibility (Workman & Kingston, 1998;
Bannister & Kouzarides, 2011). This second point contrasts histone lysine methylation
which acts more classically as only an epigenetic “mark,” where it’s function is to be
recognized by effector proteins that act positively or negatively on transcription (Martin &
Zhang, 2005). Histone methylation also differs from acetylation in that up to three methyl
groups can be transferred onto each lysine residue, each with potentially distinct
functions. For example, histone H3 lysine 9 trimethylation (H3K9me3) is associated with
transcription start sites of silent genes, whereas monomethylation (H3K9me1) is found in
mostly active gene promoters (Barski et al., 2007).
The intertwining connections between epigenetic mechanisms and disease is clear given
the power they hold over transcription. Great interest into these connections is
exemplified not only by the fact that publications on epigenetics have increased
significantly in the past two decades (Fig. 3A), but also by the increasing proportion of
publications relating epigenetics to disease (Fig. 3B). Diseases attributable to epigenetic
misregulation fit into two categories: (1) epigenetic dysfunction caused by mutations or
otherwise improper function of epigenetic-related machinery, or (2) properly functioning
epigenetic mechanisms producing inappropriate programming, inherited transgenerationally
or programmed from previous life events. While common genetic and proteomic tools can
help determine and rationalize the effects that a mutation may have, it is proving much
more difficult to probe the epigenetic component of disease when epigenetic mechanisms
are otherwise functioning normally.
Epigenetics of diabetes and metabolic syndrome
A growing body of research using the DOHaD approach is showing that exposure to
improper nutrition or endocrine disruption in utero produces epigenetic marks that are
carried through life. A rat model of intrauterine growth retardation (IUGR) is used to
study the effects of poor placental nutrient transport during pregnancy and has previously
been associated with development of T2D in offspring (Simmons, Templeton & Gertz,
2001). In this model, Pdx1, a transcription factor that regulates b cell differentiation, and
whose disruption causes T2D (Hani et al., 1999; Macfarlane et al., 1999; Leibowitz et al.,
2001), was shown to have increased promoter DNA methylation, histone H3 and H4
deacetylation, and H3K9 dimethylation in IUGR pups (Park et al., 2008). Each of these
epigenetic changes are associated with gene silencing, and in this case, were accompanied
by inhibited Pdx1 promoter binding by the transcription factor USF-1, and a 50%
decrease in Pdx1 mRNA levels in fetuses and pups that persisted into adulthood. Pdx1
expression was then rescued by a short treatment with a HAT activator in newborn pups
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(Park et al., 2008; Pinney et al., 2011). These results demonstrate that not only can an
aberrant transcriptional program be set early in life, but intervention and reversal is
possible.
The transcriptional coactivator PGC-1a also has altered epigenetic regulation in T2D.
The gene for PGC-1a, PPARGC1A, was shown to have increased promoter DNA
Figure 3 Research into the connections between epigenetics and disease has greatly increased from
1990–2015. (A) Yearly number of publications on PubMed matching combinatorial search results of
“epigenetics” keywords alone, or paired with “disease” keywords. The following search queries were used
for “epigenetics”: (epigenetic OR epigenetics OR epigenome OR “histone modification” OR “DNA
methylation” OR “histone methylation” OR “histone acetylation”), and “epigenetics and disease”:
(epigenetic OR epigenetics OR epigenome OR “histone modification” OR “DNA methylation” OR
“histone methylation” OR “histone acetylation”) AND (disease OR disorder OR cancer OR syndrome).
(B) Yearly percentage of epigenetics articles (from A) that involve disease.
Full-size DOI: 10.7717/peerj.5062/fig-3
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methylation in pancreatic islet cells of type-2 diabetics compared to non-diabetics.
This increase in DNAmethylation was correlated with decreases in PPARGC1A expression
and insulin secretion (Ling et al., 2008). PGC-1a is involved in regulating glucose
homeostasis by co-activating FOXO1 (Puigserver et al., 2003), and polymorphisms in
PPARGC1A are associated with increased risk for T2D (Pihlajama¨ki et al., 2005; Yang et al.,
2011), which may play a similar functional role in modifying PGC-1a activity as promoter
DNA methylation.
The histone H3 lysine 9 demethylase KDM3A (also known as JHDM2A) is crucially
involved in genes that regulate energy and fat metabolism. KDM3A-/- mice have many of
the signs of metabolic syndrome including insulin resistance, hypertriglyceridemia,
elevated leptin levels, and obesity (Inagaki et al., 2009). Eliminating KDM3A resulted in
the expected increase in gene-silencing H3K9me2 levels, and indeed several genes related
to anti-adipogenesis, obesity and T2D were downregulated in the knockout mice. In a
corollary study, instead of artificially increasing H3K9 levels by knocking out KDM3A,
obesity was induced dietetically in dams, and then the effect on H3K9 levels in offspring
was examined (Masuyama & Hiramatsu, 2012). Not only did these offspring perform
worse on glucose tolerance tests, and show increased insulin resistance, but levels of
leptin and adiponectin were significantly increased and decreased, respectively, which are
both changes associated with obesity (Ukkola & Santaniemi, 2002; Enriori et al., 2006;
Sa´inz et al., 2015). Increased levels of H3K9me2 were found in the promoter of
adiponectin, whereas increased levels of H4K20me1 (a permissive histone modification)
was found in the leptin promoter, suggesting that histone modifications play a significant
role in conferring obesity and metabolic syndrome phenotypes.
The effect of unfavorable environmental conditions early in life in humans is
exemplified by extensive literature on prenatal exposure to famine. The best case study is
that of the Dutch famine during the winter of 1944–1945, where those exposed prenatally
showed phenotypes such as decreased glucose-tolerance (Ravelli et al., 1998), obesity
(Ravelli, Stein & Susser, 1976; Ravelli et al., 1999), and even increased brain abnormalities
and mental disorders (Susser et al., 1996; Susser, Hoek & Brown, 1998; Brown et al., 2000;
Hulshoff Pol et al., 2000). The exact mechanisms at play are not completely understood,
but mounting evidence suggests that altered epigenetic regulation may be responsible.
Using exposed-unexposed same-sex sibling pairs, it has been shown that genes highly
involved in metabolism had significantly altered methylation levels in the famine
exposed-sibling (Heijmans et al., 2008; Tobi et al., 2009). IGF2 hypomethylation was
seen in males exposed to famine prenatally, a result that has also been correlated between
obese fathers and their offspring (Soubry et al., 2013). IGF2 is an important growth
factor during and after gestation, and therefore variable DNA methylation levels at the
IGF2 gene could influence IGF2 expression and subsequent growth rate. Indeed, this
hypothesis has some support in that brain weight is correlated with IGF2 methylation
in males (Pidsley, Dempster & Mill, 2010). Brain weight is decreased in schizophrenia,
which raises an interesting suggestion that increases in schizophrenia associated with
prenatal famine exposure may be mediated by changes in DNA methylation at the IGF2
locus, although this will involve much more research. More recently, genome-wide
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approaches to DNA methylation have explored the epigenomic effects of prenatal famine
(Tobi et al., 2014). Of interest is the finding that the insulin receptor gene (INSR) is
hypermethylated in exposed individuals, and the levels of DNA methylation at the INSR
gene is positively associated with both birth weight and LDL cholesterol. This group also
summarized differentially methylated GO terms with REVIGO analysis and found that
pathways involved in metabolism of triglycerides and lipids, regulation of growth,
polysaccharide biosynthesis, and response to activity were among those significantly
affected by prenatal famine exposure.
These results are beginning to show how adverse early-life conditions are predisposing
affected individuals to disease in late-life, however, as with other epidemiological studies,
this research area faces challenges in determining causality (Richmond et al., 2014).
The infeasibility of randomized control trials means that confounding factors, selection
bias, measurement and exposure inconsistencies between studies, and reverse causation
need to be accounted for when taking a DOHaD approach (Gage, Munafo` & Davey Smith,
2016; Yamada & Chong, 2017). The primary mechanism that is thought to translate
changes in the epigenome to a specific phenotype is the influence of epigenetic marks on
transcription factors. Transcription factor binding is influenced by the local epigenetic
landscape, either directly through changes to the binding interface, or indirectly by
influencing the recruitment of other transcriptional machinery. Examples of DOHaD
studies directly addressing this mechanism are sparse (Martin & Fry, 2016; Tilley et al.,
2018), and most epigenome wide association studies focus on enrichment of the
epigenetic marks themselves. Future studies should evaluate not only changes to the
epigenome, but also the mediators of their effects.
Gestational diabetes and the epigenome
Gestational diabetes mellitus (GDM) is glucose intolerance arising during pregnancy in
non-diabetic women. GDM creates a hyperglycemic intrauterine environment, which
predisposes offspring to a variety of metabolic disorders later in life such as T2D (Clausen
et al., 2008; Dabelea et al., 2008), metabolic syndrome (Boney et al., 2005; Clausen et al.,
2009), and possibly childhood obesity (Gillman et al., 2003; Kim et al., 2011). GDM
constitutes a form of in utero over-nutrition, and yet offspring have similar outcomes to
those who experience under-nutrition, which has led to the observation of a U-shaped
relationship between metrics such as birthweight and T2D or obesity (Pettitt & Jovanovic,
2001; Harder et al., 2007). These results suggest that GDM offspring have altered
developmental programming, which has led to several studies examining the epigenetic
impact of this in utero environment. A genome-wide DNAmethylation analysis of control
and GDM offspring revealed 1,373 and 1,418 methylation variable positions (MVPs) in
placenta and cord blood, respectively (Finer et al., 2015). These results displayed tissue-
specific differences in MVP enrichment relative to genomic features and CpG islands,
suggesting a nuanced, rather than general, effect on DNA methylation patterns. KEGG
analysis revealed a significant enrichment of MVPs in pathways such as endocytosis,
chemokine signaling, and those related to cancer and metabolism, suggesting altered gene
regulation, and potential mechanisms conferring metabolic pathogenesis later in life.
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These interpretations agree with a smaller study that examined changes in DNA
methylation genome-wide and found that indeed genes associated with metabolic diseases
were affected in infants exposed to GDM (Ruchat et al., 2013).
Other studies have taken a narrower approach to studying the consequences of
GDM, focusing on specific genes. El Hajj et al. (2013) found that the imprinted MEST
gene had lower DNA methylation levels in offspring of both dietetically- and insulin-
treated GDM mothers. This gene has not only been found to be upregulated in obese
humans (Kosaki et al., 2000) and mice (Takahashi, Kamei & Ezaki, 2005), but is correlated
specifically with fat-mass expansion (Koza et al., 2006; Jura et al., 2016). The authors
suggest that the decrease in MEST DNA methylation may contribute to the risk of
developing obesity by these offspring later in life (El Hajj et al., 2013). Another group
found increased leptin gene (LEP) promoter methylation in GDM offspring using results
from the Rhode Island Child Health Study (Lesseur et al., 2014b). Leptin is the adipokine
that signals satiety when energy stores are high, and leptin resistance is a hallmark of
obesity, meaning satiety signaling is disrupted compared to non-obese subjects (Enriori
et al., 2006). Interestingly, this same group found that LEP promoter DNA methylation
was positively associated with lethargic behavior in male infants (Lesseur et al., 2014a).
Indeed, increased LEP promoter DNA methylation occurs in rats with diet-induced
obesity as well (Milagro et al., 2009), which opens the possibility that the increased
methylation seen in GDM offspring may interact with their susceptibility to obesity. In
contrast to promoter sites, another group suggested a causal link between maternal
hyperglycemia and hypomethylation of a CpG site within the first intron of LEP, which
was negatively correlated with cord-blood leptin levels (Allard et al., 2015). The authors
suggest that given the causal role between GDM and epigenetic regulation of leptin,
early intervention by epigenetic modification may mitigate the negative metabolic effects
seen later in life.
Studies exploring the epigenetic link between GDM exposure and disease are limited
primarily by their correlative nature. Determining cause-and-effect would require
interventions that are generally not possible technologically or ethically, thus our
understanding of these processes is currently bounded to associative studies. For
obvious reasons, studies involving epigenetic analysis of neonates are confined to the
placenta and cord blood. This limits the extrapolation power of this research given how
tissue-specific epigenetic programming can be. This area will benefit from longitudinal
studies linking the epigenome of perinatal organs to the epigenome of organs and tissues
associated with the development of disease later in life.
Methyl-donor availability and methyl-metabolism
Many metabolites serve as cofactors or substrates for epigenetic enzymes (Katada,
Imhof & Sassone-Corsi, 2012; Keating & El-Osta, 2015). Of particular importance is
S-adenosyl methionine (SAM), which is the sole methyl-donor for both DNA and
histone methylation. The transfer of the methyl-group from SAM by DNA or histone
methyltransferases results in the formation of S-adenosyl homocysteine (SAH), which in
turn inhibits the activity of those methyltransferases (James et al., 2002). This means that
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modulation of SAM, SAH, and other one-carbon pathway metabolite levels can passively
regulate the activity of epigenetic methyltransferases, directly linking the epigenome to
metabolic status. In fact, it’s been shown that disrupted methyl-group metabolism in
transgenic mice leads to general hypomethylation of DNA (Chen et al., 2001; Poirier et al.,
2001). SAM is mostly derived from dietary methyl-donors such as folate, choline, and
methionine, which indicates that methylation patterns, and therefore transcriptional
patterns, can be altered directly by dietary insufficiencies (Wainfan et al., 1989; Tsujiuchi
et al., 1999). Methyl-deficiency and subsequent general DNA hypomethylation has long
been known to be carcinogenic (Wilson, Shivapurkar & Poirier, 1984; Lin et al., 2001;
Gaudet et al., 2003), specifically hypomethylation of oncogenes creates a transcriptional
environment in which they can be expressed (Feinberg & Vogelstein, 1983; Bhave, Wilson &
Poirier, 1988; Zapisek et al., 1992; Wu et al., 2005).
A powerful tool for studying the epigenetic consequences of dietary and environmental
factors is the viable yellow agouti (Avy) mouse model. In these mice, the upstream
insertion of an intracisternal A particle (IAP) retrotransposon causes constitutive
expression of the Agouti gene, which is normally silenced by DNA methylation
(Dolinoy, 2008). Due to global epigenetic reprogramming events early in development
(for review see Cantone & Fisher, 2013), disruption in the DNA methylation pathway
at this time can leave this IAP unmethylated. Offspring with full methylation capabilities
are brown, whereas those with reduced DNA methylation, either through dietary
deficiencies or non-functional epigenetic machinery, have more yellow in their coats as
DNA methylation levels decrease (Dolinoy, 2008). This means that the availability of
methyl-donors and proper methyl-metabolism in utero not only has transcriptional
consequence, but the effect of environmental stimuli on DNA methylation can be
measured by proxy through coat color. This system has been used to study the effects of
methyl-donor supplementation during pregnancy, such as folate, which is recommended
to prevent neural tube defects. Researchers have found that maternal methyl
supplementation indeed increases global DNA methylation in offspring (Cooney, Dave &
Wolff, 2002; Waterland & Jirtle, 2003), and may modify the germline epigenome and
therefore extend to further generations (Cropley et al., 2006). Methyl-donor
supplementation has since been shown to counteract potentially pathogenic DNA
hypomethylation caused by maternal exposure to the endocrine disruptor bisphenol
A (BPA) (Dolinoy, Huang & Jirtle, 2007). In this study, Dolinoy, Huang & Jirtle (2007)
found a >30% decrease in average methylation of nine CpG sites in the Avy IAP in
response to supranormal BPA treatment, and a similar decrease in the CabpIAP metastable
epiallele, suggesting high levels of BPA affects DNA methylation globally, rather than at
specific loci. BPA exposed mice supplemented with a mixture of methyl-donors (folic
acid, vitamin B12, betaine, and choline chloride) had restored DNAmethylation levels and
reduced yellow coat color compared to mice without supplementation. Similar results
have been shown in human tissues with detectable levels of BPA (Faulk et al., 2016);
however, the efficacy of methyl-donor supplementation for reducing the harmful effects of
prenatal BPA exposure in humans in still an open question.
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Cancer metabolism and epigenetics
The field of cancer epigenomics is vast and extensively reviewed (Esteller, 2008; Sharma,
Kelly & Jones, 2010; Rodrı´guez-Paredes & Esteller, 2011; Dawson & Kouzarides, 2012; You &
Jones, 2012) which is why for this review we will stay within the context of metabolism and
epigenetics with respect to cancer. Cancer is a broad grouping of diseases with an
extremely large range of phenotypes and clinical implications, all with the commonality of
unrestricted cell proliferation. Besides bypassing checkpoint mechanisms that regulate
normal cellular function, cancer cells often have modified metabolic profiles that support
continued growth and cell division.
Recently, the term “oncometabolite” has been coined to describe metabolites associated
with cancer and oncogenesis. These are normally produced metabolites, but gain “onco”-
status through mutations and malfunctions of metabolic enzymes leading to their
abnormal accumulation found in cancer cells. Metabolic enzyme mutations are common
in various cancers, for example, mutations in succinate dehydrogenase (SDH) are present
in paragangliomas, gastrointestinal stromal tumors, neuroblastomas, renal tumors, and
thyroid carcinomas (Bardella, Pollard & Tomlinson, 2011), isocitrate dehydrogenase
(IDH) mutations are in many central nervous system cancers, leukemia, prostate
cancer, and colon cancer (Yen et al., 2010), and fumarate hydratase (FH) mutations are
found in fibroids, skin, and renal cancers (Tomlinson et al., 2002; Toro et al., 2003) among
others. Oncometabolites are proving to play many roles in cancer but of particular interest
here is their action on the epigenome (Yang, Soga & Pollard, 2013). Mutations in SDH,
IDH, and FH lead to accumulation of succinate, D-2-hydroxyglutarate (2HG) and
fumarate, respectively, which then have competitive inhibitory effects on DNA and
histone demethylase enzymes (Xiao et al., 2012), suggesting that elevated methylation will
result. SDH mutations in paragangliomas show hypermethylation in gene promoters,
particularly associated with genes involved in neuroendocrine differentiation, leading to
their downregulation (Letouze´ et al., 2013). Inhibiting SDH pharmacologically increases
multiple histone H3 methylation marks which can then be rescued by the overexpression
of the histone demethylase JMJD3 (Cervera et al., 2009). SDH can also be silenced
epigenetically, seen in a patient with paragangliomas, which could provide a positive
feedback cycle where epigenetic silencing of SDH causes epigenetic silencing of other
genes (Richter et al., 2016). FH mutants exhibit similar phenotypes to SDH mutants given
their close metabolic relationship; both have shown to reduce 5hmC, which is one of the
first products in the TET2-dependent DNA demethylation pathway (Xiao et al., 2012).
In the context of oncometabolomics, SDH and FH mutants are loss-of-function
mutations whereas IDH1/IDH2 mutants are gain-of-function, producing excess
2HG, however the resultant inhibition of demethylation is similar. Multiple studies
have shown that IDH1/IDH2 mutations present in leukemia cause the accumulation
of 2HG, inhibiting DNA demethylation and producing a hypermethylation phenotype.
Hypermethylation in hematopoietic stem cells suppresses genes needed for
differentiation, causing an increase in progenitor cells and a proleukemogenic effect
(Figueroa et al., 2010; Sasaki et al., 2012). IDH1/2 mutations are also present in
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approximately 80% of grade II-III gliomas (Cohen, Holmen & Colman, 2013), producing a
CpG island hypermethylator phenotype (Noushmehr et al., 2010). This phenotype was
replicated in immortalized primary human astrocytes containing the predominant
IDH1mutation (R132H) found in low-grade gliomas (Turcan et al., 2012), demonstrating
the causal role of this single mutation. The L-2HG enantiomer also presents
oncometabolic DNA demethylation inhibitory effects in kidney tumors, however this is
due to changes in L-2HG dehydrogenase rather than IDH1/IDH2 (Shim et al., 2014).
One of the most common metabolic shifts in cancer cells is the production of lactate
from glucose even when oxygen is present, known as the Warburg effect (Kim & Dang,
2006). While the mechanisms and utility of the Warburg effect are still unclear (Liberti &
Locasale, 2016), modern epigenetic contributions have been added to the debate in an area
that was dominated by classic genetic and biochemical analysis (Wang & Jin, 2010). In
gastric cancer cell lines, fructose-1,6-bisphosphatase (FBP) is downregulated in an
NFkB-dependent manner with Ras-mediated transformations (Liu et al., 2010). When
NFkB is inhibited in these cells, the FBP1 promoter is demethylated and expression of
FBP increases, decreasing cell proliferation. This same study found that the methylation
status of the FBP1 promoter alone can predict prognosis of gastric cancers, where
individuals with unmethylated promoters have higher survival rates.
Of course, the broader metabolic status can also predispose an individual to developing
cancer. As previously mentioned, simple dietary insufficiencies of metabolites necessary
for proper methylation can result in global DNA demethylation, potentially unleashing
oncogenes. Reversing this situation by increasing one-carbon metabolite supplementation
may be a clinically relevant intervention as it has been suggested to decrease multiple
cancers including breast (Xu et al., 2009), colorectal (Kim, 2007), and lung (Heimburger
et al., 1988), however few studies have explored whether this is an epigenetic mediated
effect (Kim et al., 2001a; Du et al., 2009).
These are just a few examples that show the interconnectedness of metabolism,
epigenetics, and cancer. Much research is needed to determine exactly how much each
genetic, epigenetic, and environmental factor contributes to oncogenesis. The result of
these studies will allow for the development of pharmacological or targeted epigenetic
interventions to compliment or replace the current portfolio of chemotherapeutic and
radiological treatments.
CONTROL OF METABOLISM: LESSONS FROM NATURE
Natural models for manipulating metabolism can serve as great resources for inspiring
treatments for many diseases. Our lab and others study animals that can survive freezing,
anoxia, severe dehydration, and hibernation. Animals that survive these conditions all
use metabolic rate depression and metabolic reorganization as adaptations to conserve
energy and enact cytoprotective strategies. For example, the wood frog (Rana sylvatica)
survives whole body freezing in the winter, in part by producing huge amounts of
glucose as a cryoprotectant, elevating plasma glucose levels to 200 mM (human type-2
diabetics >10 mM are considered hyperglycemic), and yet do not suffer the damage or
cytotoxicity associated with diabetes (Storey & Storey, 1984). Much research has been done
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to uncover the metabolic processes that allow this adaptation to occur (Storey, 1990; Storey
& Storey, 2004, 2017), and we are just beginning to explore the potential involvement
of epigenetic mechanisms. Our recent work has shown that the wood frog globally reduces
H3K4me1 levels, a permissive histone modification, but maintains H3K9me3 content,
a modification associated with gene silencing, while frozen (Hawkins & Storey, 2018).
This result is in line with the metabolic reorganization that the wood frog undergoes
where expression of most genes are downregulated to conserve energy resources under
the anoxic conditions of the frozen state. We have also shown that frozen wood frogs
suppress cyclins and cyclin-dependent kinases to gain potential energy savings by
halting cell cycle activity (Zhang & Storey, 2012). Future studies will evaluate the
involvement of other epigenetic mechanisms and their regulation of specific genes to
further elucidate the mechanisms involved in surviving freezing and its associated
extreme glucose levels.
Mammals such as the hibernating 13-lined ground squirrel (Ictidomys tridecemlineatus)
may aid us in the quest to improve tissue and organ preservation for medical
transplantation. When torpid they substantially decrease their body temperature and rates
of heartbeat, breathing, and organ perfusion rate (Carey, Andrews & Martin, 2003;
Storey & Storey, 2005). How they coordinate and regulate all of these may provide lessons
which could help us extend organ storage time to increase the window of viability for
successful transplantation. We have shown that during hibernation these animals
increase protein and activity levels of HDACs and DNMTs, as well as global DNA
methylation in a tissue specific manner (Morin & Storey, 2006; Biggar & Storey, 2014;
Alvarado et al., 2015), all of which suggest global gene silencing is taking place. Moreover,
differential regulation of microRNAs occurs in ground squirrels during hibernation
and is postulated to be involved in regulating suppression of various cellular processes
including reducing cell cycle activity during hibernation (Wu et al., 2016). Increased
DNA methylation was also seen in anoxia tolerant turtles (Trachemys scripta elegans)
(Wijenayake & Storey, 2016) that can survive without oxygen for weeks at a time. However,
despite global metabolic rate depression, selective upregulation of some beneficial
pathways is possible. For example, the DNA binding activity of NFkB increased in
anoxic turtles, causing an increase in the transcription of downstream genes under its
control (Krivoruchko & Storey, 2010). Other animals such as the naked mole-rat
(Heterocephalus glaber) have yet to be studied in terms of epigenetic mechanisms, but they
may potentially have much to offer towards our understanding of cancer, aging, and
metabolic regulation since these animals are the longest-living rodents and are uniquely
resistant to cancer (Buffenstein, 2005; Liang et al., 2010). Inspiration from these animals
and others that can endure extreme environmental stress could be combined to create
targeted therapeutics as treatments for disease.
CONCLUSION
Regulation of gene transcription is multifaceted, with innumerable possibilities for errors
to occur. Since metabolism both affects and is affected by transcriptional regulation,
when errors do occur, metabolism at all scales is disrupted, from systemic insulin
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dysregulation in T2D to aerobic glycolysis in individual cancer cells. Each of the areas
discussed in this review are still being actively researched and adding to our understanding
of how we may be able to control transcription to treat these pathologies as they
appear. The introduction of new technologies will further our abilities to probe the
structure of genes, their functional elements, epigenetic regulation, and the interactions
that each of these have with the environment.
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